NCT07513441招募中1 期
Interventional, Open-label, Trial Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF28996 in Chinese Men and Women With Parkinson's Disease
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 4
- 主要终点
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)
研究概览
简要总结
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant is Chinese, defined as having four Chinese grandparents being born in China.
- •The participant is diagnosed with idiopathic Parkinson's disease (consistent with the United Kingdom PD Society Brain Bank Criteria for the Diagnosis of PD).
- •The participant's Modified Hoehn and Yahr score is ≥2 and ≤4 (in OFF) and ≤3 in the ON state.
- •The participant experiences well recognizable and predictable motor fluctuations in the awake time including predictable morning OFF episodes causing clinically significant disability during the last 3 months prior to screening, as evaluated by the investigator.
排除标准
- •The participant has received oral or transdermal dopamine agonist treatment ≤4 weeks prior to screening.
- •The participant has undergone a neurosurgical intervention for Parkinson's disease (such as pallidotomy, thalamotomy, foetal or stem cell transplantation or deep brain stimulation).
- •The participant has any other disorder for which the treatment takes priority over treatment of Parkinson's disease or is likely to interfere with trial treatment or impair treatment compliance.
- •The participant has received Traditional Chinese Medicine treatment ≤4 weeks prior to screening.
- •Note: Other protocol-defined inclusion and exclusion criteria may apply.
结局指标
主要结局
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
时间窗: Up to 60 days
Area Under the Plasma Concentration-time Curve From Zero to Last Quantifiable Concentration (AUC0-tlast) of Lu AF28996
时间窗: Days 1, 21 or 31, and 41
Maximum Observed Plasma Concentration (Cmax) of Lu AF28996
时间窗: Days 1, 21 or 31, and 41
Time to Reach Cmax (Tmax) of Lu AF28996
时间窗: Days 1, 21 or 31, and 41
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
招募中
1 期
A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have NarcolepsyNCT07613710H. Lundbeck A/S104
招募中
2 期
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisSLE - Systemic Lupus ErythematosusLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVSystemic Lupus ErythematosusLupus NephritisNCT07570862Fate Therapeutics53
招募中
1 期
A Study of LY4302814 in Healthy ParticipantsHealthyNCT07566338Eli Lilly and Company150
已完成
1 期
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.NCT07284173Pfizer18
尚未招募
1 期
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)Inflammatory Bowel Diseases (IBD)NCT07544160iCell Gene Therapeutics18